GetTopicDetailResponse(id=e76483400a4, topicName=胃食管交界處腺癌, introduction=胃食管交界處腺癌, content=null, image=null, comments=2, allHits=1624, url=https://h5.medsci.cn/topic?id=83400, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11856, tagList=[TagDto(tagId=11856, tagName=胃食管交界處腺癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2252881, encodeId=346c225288150, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a> <a href='/topic/show?id=e76483400a4' target=_blank style='color:#2F92EE;'>#胃食管交界處腺癌#</a>, objectTitle=BMJ：替雷利珠單抗聯(lián)合化療作為一線治療晚期胃癌或胃食管結(jié)合部腺癌的療效和安全性, objectType=article, longId=864109, objectId=9f23864109d5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241219/1734601632060_8538692.png, objectUrl=/article/show_article.do?id=9f23864109d5, replyNumber=0, likeNumber=34, createdTime=2025-02-20, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=9f23864109d5, moduleTitle=BMJ：替雷利珠單抗聯(lián)合化療作為一線治療晚期胃癌或胃食管結(jié)合部腺癌的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9f23864109d5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2230522, encodeId=0569223052235, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=e76483400a4' target=_blank style='color:#2F92EE;'>#胃食管交界處腺癌#</a> <a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循環(huán)腫瘤DNA#</a>, objectTitle=Gastric Cancer：循環(huán)腫瘤DNA可預測可切除胃癌和胃食管結(jié)合部癌患者的復發(fā)和生存, objectType=article, longId=846688, objectId=019f846688c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240918/1726648847934_8538692.png, objectUrl=/article/show_article.do?id=019f846688c9, replyNumber=0, likeNumber=0, createdTime=2024-10-12, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=019f846688c9, moduleTitle=Gastric Cancer：循環(huán)腫瘤DNA可預測可切除胃癌和胃食管結(jié)合部癌患者的復發(fā)和生存, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=019f846688c9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2150920, encodeId=e75021509207a, content=<a href='/topic/show?id=e76483400a4' target=_blank style='color:#2F92EE;'>#胃食管交界處腺癌#</a> 對于人表皮生長因子受體2 (HER2)陰性、局部晚期不可切除或轉(zhuǎn)移性胃或胃食管交界處(mG/GEJ)腺癌患者，迫切需要一線治療方案。Claudin-18亞型2 (CLDN18.2)在正常胃細胞中表達，在惡性G/GEJ腺癌細胞中維持。
2023年7月31日，中山大學徐瑞華團隊在Nature Medicine在線發(fā)表題為“Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial”的研究論文，該研究報道了佐妥昔單抗(一種靶向CLDN18.2的單克隆抗體)聯(lián)合卡培他濱和奧沙利鉑(CAPOX)作為CLDN18.2陽性、HER2陰性、局部晚期不可切除或mG/GEJ腺癌的一線治療。, objectTitle=胃食管交界處腺癌, objectType=topic, longId=83400, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=109, createdTime=2023-08-02, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2123428, encodeId=08c62123428a4, content=<a href='/topic/show?id=8a3b458198d' target=_blank style='color:#2F92EE;'>#安斯泰來#</a>首個#Claudin18.2#抗體<a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>治療cldn18.2陽性<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>或<a href='/topic/show?id=e76483400a4' target=_blank style='color:#2F92EE;'>#胃食管交界處腺癌#</a>三期臨床成功, objectTitle=安斯泰來首個Claudin18.2抗體Zolbetuximab治療cldn18.2陽性胃腺癌或胃食管交界處腺癌三期臨床成功, objectType=article, longId=748418, objectId=1b26e4841834, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221115/f069d202c06243898f827e66b9c8c8af.jpg, objectUrl=/article/show_article.do?id=1b26e4841834, replyNumber=0, likeNumber=130, createdTime=2023-04-03, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1b26e4841834, moduleTitle=安斯泰來首個Claudin18.2抗體Zolbetuximab治療cldn18.2陽性胃腺癌或胃食管交界處腺癌三期臨床成功, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1b26e4841834)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
前往app查看評論內(nèi)容
#胃食管交界處腺癌# 對于人表皮生長因子受體2 (HER2)陰性、局部晚期不可切除或轉(zhuǎn)移性胃或胃食管交界處(mG/GEJ)腺癌患者，迫切需要一線治療方案。Claudin-18亞型2 (CLDN18.2)在正常胃細胞中表達，在惡性G/GEJ腺癌細胞中維持。
2023年7月31日，中山大學徐瑞華團隊在Nature Medicine在線發(fā)表題為“Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial”的研究論文，該研究報道了佐妥昔單抗(一種靶向CLDN18.2的單克隆抗體)聯(lián)合卡培他濱和奧沙利鉑(CAPOX)作為CLDN18.2陽性、HER2陰性、局部晚期不可切除或mG/GEJ腺癌的一線治療。
